Sangui Biotech International Stock Annual Yield
| SGBI Stock | USD 0 0.00 0.00% |
Sangui Biotech International fundamentals help investors to digest information that contributes to Sangui Biotech's financial success or failures. It also enables traders to predict the movement of Sangui Pink Sheet. The fundamental analysis module provides a way to measure Sangui Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sangui Biotech pink sheet.
Sangui |
Sangui Biotech International Company Annual Yield Analysis
Sangui Biotech's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Sangui Biotech International has an Annual Yield of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Sangui Fundamentals
| Return On Asset | -0.64 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.50) % | |||
| Current Valuation | 1.68 M | |||
| Shares Outstanding | 209.9 M | |||
| Shares Owned By Insiders | 13.03 % | |||
| Price To Earning | (18.33) X | |||
| Price To Book | 46.44 X | |||
| Price To Sales | 10.09 X | |||
| Revenue | 69.19 K | |||
| Gross Profit | 69.19 K | |||
| EBITDA | (18.44 K) | |||
| Net Income | (63.34 K) | |||
| Cash And Equivalents | 30.47 K | |||
| Total Debt | 48.9 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (140.46 K) | |||
| Beta | 0.22 | |||
| Market Capitalization | 902.58 K | |||
| Total Asset | 130.79 K | |||
| Retained Earnings | (37 M) | |||
| Net Asset | 130.79 K |
About Sangui Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangui Biotech International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangui Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangui Biotech International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sangui Pink Sheet
Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.